Testosterone for Fatigue in Men With MS
NCT03000127
Withdrawn
Fatigue is a major symptom in people with multiple sclerosis (MS), for which treatments are limited. Several studies have shown that a large proportion of men with MS have low testosterone levels. We propose a two-site clinical trial using topical testosterone gel as a treatment for MS-related fatigue in men with progressive MS who have low or low-normal testosterone levels.
Gender:
MALE
Ages:
Between 18 years and 60 years
Trial Updated:
11/04/2019
Locations: University of California, Los Angeles, Los Angeles, California +1 locations
Conditions: Multiple Sclerosis
Register for Updates
PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women
NCT01364623
Completed
The purpose of this study was to assess the bioavailability of total testosterone through pharmacokinetic profiles obtained following (a) single administration of three doses of TBS-2 b) multiple administration TBS-2. In addition, assessing the bioavailability of free testosterone, dihydrotestosterone, SHBG and estradiol through pharmacokinetic profiles was also conducted.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
10/04/2019
Locations: Premier Research International LLC, Austin, Texas
Conditions: Female Sexual Dysfunction
Register for Updates
Hypogonadism in Young Men With Type 2 Diabetes
NCT01155518
Terminated
Low testosterone production, known clinically as hypogonadism, appears to be common complication of type 2 diabetes, affecting one in three diabetic men. Hypogonadism is known to be associated with decreased muscle mass, increased fat mass, increased inflammation and decreased fertility. In this grant, the investigators propose to study the effects of having low testosterone on 1) insulin sensitivity, the ability of the body to handle glucose 2) fat and muscle mass at specific areas of the body... Read More
Gender:
MALE
Ages:
Between 18 years and 40 years
Trial Updated:
10/03/2019
Locations: Millard Fillmore Gates Hospital, Buffalo, New York
Conditions: Hypogonadotropic Hypogonadism, Type 2 Diabetes
Register for Updates
Dose-Response of Gonadal Steroids and Bone Turnover in Older Men
NCT00114114
Completed
The purpose of this study is to determine the levels of testosterone and/or estradiol at which changes in bone turnover, body composition, strength, sexual function etc. begin to occur in older men. This information may help determine when to intervene with hormone replacement therapy in aging men.
Gender:
MALE
Ages:
Between 60 years and 75 years
Trial Updated:
09/27/2019
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Healthy Volunteers
Register for Updates
Subcutaneous vs. Intramuscular Testosterone
NCT03091348
Completed
In this randomized, cross-over study 20 subjects who are undergoing testosterone (T) therapy for the treatment of T deficiency will receive both subcutaneous testosterone therapy and intramuscular testosterone therapy. One group will receive a SQ injection followed by an IM injection and one group will receive an IM injection followed by a SQ injection. The primary objective of this study is to measure testosterone concentration in men after these two treatment routes and determine if there are... Read More
Gender:
MALE
Ages:
Between 18 years and 90 years
Trial Updated:
09/27/2019
Locations: Men's Health Boston, Chestnut Hill, Massachusetts
Conditions: Testosterone Deficiency, Hypogonadism, Male
Register for Updates
Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT02513940
Completed
Torsades de pointes (TdP) is a potentially fatal ventricular arrhythmia associated with corrected QT (QTc) interval prolongation. More than 50 commonly used drugs available on the US market may cause QTc interval prolongation and TdP. While TdP occurs more commonly in women, 33-45% of all cases of TdP have occurred in men. Older age is a risk factor for drug-induced TdP in men, possibly due to declining serum testosterone concentrations. Available evidence shows an inverse relationship between Q... Read More
Gender:
MALE
Ages:
65 years and above
Trial Updated:
08/15/2019
Locations: Indiana University, Indianapolis, Indiana
Conditions: Long QT Syndrome
Register for Updates
28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men
NCT03298373
Unknown
This is a Phase I multicenter, double-blind, repeat dose, dose-escalating study, in healthy men to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC).
Gender:
MALE
Ages:
Between 18 years and 50 years
Trial Updated:
08/09/2019
Locations: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California +1 locations
Conditions: Healthy Men, Male Contraception
Register for Updates
Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men
NCT02754687
Unknown
The long term objective is to develop a new male hormone 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) as a male hormonal contraceptive.
Gender:
MALE
Ages:
Between 18 years and 50 years
Trial Updated:
08/09/2019
Locations: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California +1 locations
Conditions: Healthy Men, Male Contraception
Register for Updates
Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men
NCT00365794
Completed
A. HYPOTHESES: In older men low testosterone levels, abdominal obesity and elevated fasting insulin who are at risk for the cardiovascular complications such as heart attack and stroke. 1. Supplemental testosterone will decrease abdominal adipose tissue and hepatic fat) and appendicular fat and intramyocellular lipid in peripheral muscles (IMCL). 2. Supplemental testosterone will improve insulin sensitivity by: 1. Decreasing hepatic glucose output (HGO), a measure of central insulin resista... Read More
Gender:
MALE
Ages:
Between 60 years and 90 years
Trial Updated:
08/07/2019
Locations: LAC-USC Medical Center GCRC, Los Angeles, California
Conditions: Aging, Obesity, Insulin Resistance, Hypogonadism
Register for Updates
Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes
NCT03973840
Completed
To describe the rate of post-collection TU to testosterone conversion, as manifested by increases in testosterone concentration, in Plain tubes held at room temperature and sodium fluoride (NaF)-ethylenediaminetetraacetic acid (EDTA) tubes held at room temperature or on ice prior to centrifugation
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
07/08/2019
Locations: Clarus Therapeutics, Inc, Northbrook, Illinois
Conditions: Hypogonadism, Male
Register for Updates
Impact of Estradiol Addback
NCT01862835
Completed
Repletion of testosterone (T) in older men drives Growth Hormone secretion after its aromatization to estradiol (E2) by potentiating endogenous GH drive.
Gender:
MALE
Ages:
Between 60 years and 80 years
Trial Updated:
06/05/2019
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Normal Healthy Volunteers
Register for Updates
Testosterone Replacement in Renal Failure
NCT02712944
Terminated
The purpose of this trial is to evaluate the effect of testosterone replacement in men with renal failure (on dialysis) who also have low testosterone. Specifically, the investigators will assess the change in requirement of Erythropoietin Stimulating agents.
Gender:
MALE
Ages:
Between 18 years and 80 years
Trial Updated:
05/23/2019
Locations: TTUHSC-Permian Basin, Odessa, Texas
Conditions: Hypogonadism
Register for Updates